Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-2.46/-2.61
|
|
Enterprise Value
205.99M
|
| Balance Sheet |
|
Book Value Per Share
7.90
|
| Cash Flow |
|
Cash Flow Yield
--
|
| Income Statement |
|
Total Revenue
205.76M
|
|
Operating Revenue Per Share
9.25
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others. |

6.61 
